A technology serving human factors

Epileptic seizures, anaphylactic shock, or chemical attacks—different causes that all lead to an emergency situation: rapid intervention is required to save a patient's life!

You may be a rescuer, a simple customer in a restaurant, or even a grandparent, aunt, or cousin looking after children during the holidays… You are all unique due to your physical attributes, reactions, training, or experiences, especially in emergency situations.

To address this human diversity, we created a single ZENEO® that can be used by everyone. Every detail of the device has been designed and refined with potential users, observing and analyzing their reactions, perceptions, and handling to meet both conscious and unconscious needs, aiming to prevent that small fatal mistake and eliminate any difficulty or hesitation.

The use of ZENEO® is not only safe and effective, but also designed to be easy, intuitive, fast, and “comfortable” so that you dare and succeed: because every second counts!

"When a life is at stake, the user reacts in a unique way! I’ve seen so many unexpected interpretations and unimaginable manipulations during the development of ZENEO®. Users are who they are, they are 'real'; they don’t fake it in an emergency. They are never wrong: that’s my assumption. Human factors engineering must: 'work with and for the human.' So, we created this unique ZENEO® interface, designed to reassure all users and tell them, 'Go ahead, you can do it, it will work, you will save the patient.' And it really works!"
Frédéric MABILE
Head of Human Factors Engineering

Key figures

On average, less than one minute to save a life with ZENEO®.

1,300 participants included in tests over the past 20 years.

One-third of participants find the device easy to use, while two-thirds find it very easy.

Latest validation study: 100% of injections successfully performed.

On average, for the first use of ZENEO®, it takes 45 seconds from opening the case to the "click" that saves the patient. Less than one minute to save a life.
Over 1,300 participants included in our iterative studies over the past 20 years to minimize the probability of errors.
In 2022 (validation in the USA), 60 participants simulated an injection evaluated on 15 criteria: 4 errors were identified, resulting in a 99.6% success rate.
In-depth studies with all types of users: patients with rheumatoid arthritis.
Development studies with The Use Factory in France.
Simulation of a chemical attack in the USA in 2024.
75 participants – 375 simulated injections – Only 5 in the arm and 1 on the back of the thigh, despite sometimes extreme simulated conditions (respirator, CBRN suit, slippery gloves, sirens, dim lights, and flashes). This resulted in 98.4% of injections on the thigh (top and side).
All types of potential users are evaluated in their environments.
ZENEO® allows use right at the point of crisis, especially without a needle.
Realistic environments that do not hinder proper use.
Study of use in a real-life environment: discovering the device with family.